Table 1.
Characteristics of patients who received immune checkpoint blockade monotherapies.
| Meflin expression | P-valuea | ||
|---|---|---|---|
| Variable | High | Low | |
| Median age–yr (range) | 70 (42–85) | 69 (43–80) | 0.920b |
| Sex–no. (%) | 0.663 | ||
| Female | 23 (36.5%) | 11 (31.4%) | |
| Male | 40 (63.5%) | 24 (68.6%) | |
| Subtype–no. (%) | 0.0813 | ||
| Squamous cell carcinoma (LUSC) | 17 (27.0%) | 3 (8.6%) | |
| Adenocarcinoma (LUAD) | 37 (58.7%) | 27 (77.1%)c | |
| Others | 9 (14.3%) | 5 (14.3%) | |
| Targetable EGFR mutation in LUAD–no. (%) | >0.999 | ||
| Not detected | 26 (70.3%) | 17 (68.0%)c | |
| Detected | 11 (29.7%) | 8 (32.0%) | |
| PD-L1 TPSd–no. (%) | 0.139 | ||
| <1% | 16 (26.2%) | 7 (20.6%) | |
| 1–49% | 18 (29.5%) | 17 (50.0%) | |
| 50%≤ | 27 (44.3%) | 10 (29.4%) | |
| Brinkman indexe–no. (%) | 0.525 | ||
| <400 | 26 (41.3%) | 12 (34.3%) | |
| 400≤ | 37 (58.7%) | 23 (65.7%) | |
| ECOG-PS–no. (%) | 0.255 | ||
| 2≤ (Poor) | 8 (12.7%) | 8 (22.9%) | |
| 0 or 1 (Good) | 55 (87.3%) | 27 (77.1%) | |
| Tx linef–no. (%) | 0.0046 | ||
| 1L or 2L | 46 (73.0%) | 15 (42.9%) | |
| 3L≤ | 17 (27.0%) | 20 (57.1%) | |
a
Fisher’s exact test.
b
Mann–Whitney U test.
c
One patient with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
d
Tumor Proportion Score was the percentage of viable tumor cells showing partial or complete membrane staining at any intensity.
e
Brinkman index was defined as the number of cigarettes smoked per day multiplied by the number of years of smoking (e.g., if one smoked 20 cigarettes per day for 20 yr, the Brinkman index is 400).
f
Only conventional cytotoxic chemotherapeutics were considered in the treatment line.
P-values in bold showed statistically significant differences.